Research Protocol for an Observational Health Data Analysis on the Adverse Events of Systemic Treatment in Patients with Metastatic Hormone-sensitive Prostate Cancer: Big Data Analytics Using the PIONEER Platform-Reference-Cited by-同舟云学术

Research Protocol for an Observational Health Data Analysis on the Adverse Events of Systemic Treatment in Patients with Metastatic Hormone-sensitive Prostate Cancer: Big Data Analytics Using the PIONEER Platform

Published:2024-05 Issue: Volume:63 Page:81-88
ISSN:2666-1683
Container-title:European Urology Open Science
language:en
Short-container-title:European Urology Open Science

Author:

Rajwa Pawel^ORCID,Borkowetz Angelika,Abbott Thomas,Alberti Andrea,Bjartell Anders,Brash James T.,Campi Riccardo,Chilelli Andrew,Conover Mitchell,Constantinovici Niculae,Davies Eleanor,De Meulder Bertrand,Eid Sherrine,Gacci Mauro,Golozar Asieh,Hafeez Haroon,Haque Samiul,Hijazy Ayman,Hulsen Tim,Josefsson Andreas,Khalid Sara,Kolde Raivo,Kotik Daniel,Kurki Samu,Lambrecht Mark,Leung Chi-Ho,Moreno Julia,Nicoletti Rossella,Nieboer Daan,Oja Marek,Palanisamy Soundarya,Prinsen Peter,Reich Christian,Raffaele Resta Giulio,Ribal Maria J.,Gómez Rivas Juan,Smith Emma,Snijder Robert,Steinbeisser Carl,Vandenberghe Frederik,Cornford Philip,Evans-Axelsson Susan,N'Dow James,Willemse Peter-Paul M.

Funder

Innovative Medicines Initiative

Publisher

Elsevier BV

Reference19 articles.

1. Androgen receptor signaling inhibitors in addition to docetaxel with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis;Yanagisawa;Eur Urol,2022

2. First-line systemic treatment options for metastatic castration-sensitive prostate cancer: a living systematic review and network meta-analysis;Riaz;JAMA Oncol,2023

3. Indirect comparisons of efficacy between combination approaches in metastatic hormone-sensitive prostate cancer: a systematic review and network meta-analysis;Sathianathen;Eur Urol,2020

4. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design;Fizazi;Lancet,2022

5. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer;Smith;N Engl J Med,2022

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Transforming a Large-Scale Prostate Cancer Outcomes Dataset to the OMOP Common Data Model—Experiences from a Scientific Data Holder’s Perspective;Cancers;2024-05-30